Beyond Chemotherapy: Unlocking Therapeutic Strategies in Osteosarcoma
Free
- Length
- 1 hr 30 min
- Platform
- Zoom
- Topic
- Medical & Clinical
About this webinar
While standard adjuvant chemotherapy for osteosarcoma (OS) is well established, survival rates for adolescent and young adult (AYA) patients have hit a plateau. To break through this ceiling, the field is rapidly pivoting toward the tumor microenvironment (TME) and novel targeted agents. This educational session bridges cutting-edge translational science with clinical application, highlighting the major role of the TME—specifically macrophage activation via immunotherapeutic agents like mifamurtide—alongside the next wave of therapeutics, including Tyrosine Kinase Inhibitors (TKIs) and CAR-T cell therapies.
Learning Objectives
- Evaluate the role of the tumor microenvironment in osteosarcoma, specifically how macrophage activation impacts patient outcomes.
- Analyze the clinical utility and recent European and North American Data regarding Tyrosine Kinase Inhibitors (TKIs) and novel targeted agents.
- Assess the emerging landscape of cellular immunotherapies, including CAR-T cells and antibody-drug conjugates (ADCs), for refractory or metastatic disease.
This is an independent educational activity supported by an unrestricted educational grant from ESTEVE. The scientific programme and content are developed independently by the scientific committee without influence from ESTEVE.



